CHGA — Change Agents Share News
0.000.00%
Brief: Avalon Globocare Corp - On Jan 20, Received Letter From Staff Of Nasdaq Indicating That It Has Regained Compliance With Minimum Bid Requirement
Brief: Avalon GloboCare Announces Issuance Of Key U.S. Patent For Multiple Novel QTY-Code Modified Cytokine And Chemokine Protein Receptor Molecules
Brief: Avalon GloboCare Continues Its U.S. Centric Strategy With A New Proposed Board Composition In Preparation For Acquisition Of Laboratory Services MSO
Avalon GloboCare rises on laboratory services deal
Brief: Avalon Globocare To Acquire Leading Laboratory With 2021 Unaudited Revenue Of Over $25 Mln
Brief: Avalon Globocare Receives Allowance For Joint U.S. Patent
Brief: Avalon Globocare Says Entered Into And Closed A Debt Settlement Agreement And Release With Wenzhao Lu
Brief: Avalon Globocare Corp Announces New Study Applying Artificial Intelligence (AI) Enhanced Protein Design "Qty Code" Technology
Brief: Avalon Globocare Corp Files For Mixed Shelf Of Up To $50 Mln
Brief: Avalon Globocare Signs MoU With Lu Daopei Hematology Institute To Develop Companion Diagnostics For Cellular Therapy
Brief: Avalon Globocare Expands Its Cellular Immuno-Oncology Platform With The Addition Of Novel Car-Nk Cell Therapies
Brief: Avalon Globocare Corp - Intended Senlangbio Acquisition Terminated, Eliminating Potential 80 Million Share Issuance
Brief: Avalon Globocare Drew Down An Additional Aggregate Of $1 Mln From Credit Facility
Brief: Avalon Globocare Jointly Files U.S. And International Patent Application For Breakthrough S-Layer Coated Emulsome Technology (SLET)
Brief: Upmc And Pitt Develop New Cancer Immunotherapy With Avalon Globocare
Brief: Avalon GloboCare Says SenlangBio Has Initiated First-In-Human Clinical Trial In Recurrent Brain Cancer
Brief: Avalon Globocare CEO Provides Letter To Update Shareholders About Acquisition Of Senlangbio
NASDAQ RESUMED AT 09:55 AM
Brief: Avalon Globocare Announces Execution Of Purchase Agreement For Acquisition Of Senlangbio In All Stock Transaction